CELU | Jotup

Celularity Inc. to Host Investor and Analyst Research & Development Day

Retrieved on:

Lundi, avril 22, 2024

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day.

Key Points:

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day.
The Investor and R&D Day, scheduled for Tuesday, May 21, 2024, from 12:00 p.m. to 4:00 p.m.
The event will feature members of Celularity’s executive management team, including:
A live webcast of the Investor and Analyst R&D Day can be accessed by visiting the Investor Relations section of Celularity's website at www.celularity.com .
“We are very excited to host our first on-site and virtual Investor and Analyst R&D Day at our world-class headquarters, research, and manufacturing center.

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Retrieved on:

Vendredi, avril 19, 2024

CELU, Annual report, Security (finance), Regenerative medicine, Calendar

Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.

Key Points:

Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.
The Company intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period.
However, there can be no assurance that the Company will regain compliance within the compliance period, or maintain compliance with the other Nasdaq listing requirements.
The Company is working diligently to file its Annual Report on Form 10-K and will provide an update once more information is available.

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Retrieved on:

Jeudi, avril 18, 2024

USD, Mayo Clinic, CELU, Management, CTM, DSM-IV codes, Conference, Development, Engineering, Clinical professor, UCM, Patient, Extracellular matrix, Healing, Regenerative medicine, Regeneration, Therapy

The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”

Key Points:

The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”
Celularity’s abstract explores the application of various decellularized placental biomaterials, including connective tissue matrix (CTM) and umbilical cord matrix (UCM), in tendon management, both in vitro and in vivo.
The abstract focuses on assessing the biomaterials’ biomechanical properties, immunomodulatory effects, and preclinical outcomes in clinically relevant models to advance their potential in tendon repair.
I am very excited about the growing opportunity and potential of our decellularized placental biomaterials in tendon management and healing.
These data indicate that human placental decellularized biomaterials may represent a promising matrix suitable for tendon management and healing.

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Retrieved on:

Lundi, avril 15, 2024

Pelvis, Burns, Umbilical cord, Tissue, CELU, Extremities, Form, Environment, Extracellular matrix, Good manufacturing practice, Regenerative medicine, Growth, Medical imaging

FLORHAM PARK, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”) a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

Key Points:

Celularity’s predecessor company was an early innovator in the field of placental-derived biomaterials, and today we continue to develop innovative, next-generation products in this technology.
Under the plan implemented, senior executives are foregoing a portion of their 2024 cash salary as well as payment in cash of any performance bonus payable in 2024.
Celularity’s advanced biomaterial product pipeline consists of four commercial-stage products and three investigational products.
Interfyl®, a decellularized human placental connective tissue matrix designed for use to replace or supplement damaged or inadequate integumental tissue.

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Retrieved on:

Lundi, avril 8, 2024

CELU, Notifiable disease, Cell, Inflammation, Tissue, Gene, Cancer, SASP, Ageing, Society, Heart, NK, Annual general meeting, Vaccine

The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.

Key Points:

The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.
Senescent cells are key drivers in the process of age-related cellular corruption at the heart of degenerative diseases, cancer and immuno-senescence (the progressive decline in immune function that occurs with age).
Moreover, if not eliminated, these cells impair the normal regenerative process that restores function to organs and tissues.
Celularity believes these preclinical data demonstrate the potential of its assets to target and selectively remove damaged and abnormal cells expressing stress ligands, such as senescent, virally infected and cancer cells.

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Retrieved on:

Mardi, mars 26, 2024

CELU, HCPCS, Growth, Regenerative medicine, Medicare, CMS

The designated HCPCS Q code is Q4283 and is available starting April 1, 2024.

Key Points:

The designated HCPCS Q code is Q4283 and is available starting April 1, 2024.
"The HCPCS Q code approval by CMS further recognizes Biovance® 3L as an important therapeutic option for the treatment of wounds,” said Dr. Robert J. Hariri, M.D., Ph.D., Celularity CEO, chairman and founder.
“The medical community has been rapidly adopting this product, and the HCPCS Q code approval paves the way for Biovance® 3L to realize additional growth, enabling the potential to impact more lives.
We will continue to innovate in this important part of our business and look forward to providing future updates.”
The Healthcare Common Procedure Coding System (HCPCS) is produced by the Centers for Medicare and Medicaid Services (CMS).

Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm

Retrieved on:

Vendredi, mars 22, 2024

CELU, PLLC, Human

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc. (NASDAQ: CELU) breached their fiduciary duties to shareholders.

Key Points:

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc. (NASDAQ: CELU) breached their fiduciary duties to shareholders.
Kuehn Law pays all case costs and does not charge its investor clients.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets.

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Retrieved on:

Mercredi, mars 20, 2024

CELU, Diagnosis, Shoulder, Biologics license application, Disease, Risk, Patient, Microsoft Exchange Server, Stem cell, IND, Facioscapulohumeral muscular dystrophy, Regenerative medicine, FDA, BLA, FSHD, Muscular dystrophy, Food, Pharmaceutical industry

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).

Key Points:

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).
Orphan drug designation is a status given to drugs that show the potential to treat, prevent or diagnose serious or life-threatening diseases that affect fewer than 200,000 people in the U.S.
Earlier, Celularity received FDA Investigational New Drug Application clearance for PDA-002 in FSHD and plans to commence a phase 1/2 study in the second half of 2024.
The trial serves as an important component for submitting a Biologics License Application (BLA) to the FDA in the future as a potential treatment for FSHD and other types of muscular dystrophy.

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

Retrieved on:

Jeudi, mars 14, 2024

CELU, Cell, Tissue, Research, Sarcopenia, Cornell University, Cancer, Biology, Pulse, Regenerative medicine, Immunity, Placenta, Singularity Group, Immunosenescence, Movement, Autoimmunity, Ageing, Medicine

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.

Key Points:

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.
Dr. Hariri has led the effort to harness the unique biology of placental-derived cells in a range of clinical indications, including cancer, autoimmune and degenerative diseases.
“Dr.
This work puts Dr. Hariri at the forefront of the longevity movement, with his finger on the pulse of the ever-changing landscape.”
The ABUNDANCE Summit will occur in Los Angeles, Calif., from March 17 through 21, 2024.

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Retrieved on:

Mardi, mars 12, 2024

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

Key Points:

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
Dr. Hariri’s keynote, titled, “Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders,” will address cellular immunotherapy’s broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson’s disease.
Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to age-related cognitive decline.
SBMT’s 21st Annual World Congress will take place in Los Angeles, Calif., on March 14 through 17, 2024.